以HDAC为靶点的抗三阴性乳腺癌研究进展

基础医学与临床 ›› 2018, Vol. 38 ›› Issue (11): 1625-1629.

以HDAC为靶点的抗三阴性乳腺癌研究进展

王发玲¹,谢珂²,王艳林³,曹春雨²

1. 三峡大学肿瘤微环境与免疫治疗湖北省重点实验室
2. 三峡大学医学院
3. 三峡大学分子生物学研究所

收稿日期:2017-06-22 修回日期:2017-11-03 出版日期:2018-11-05 发布日期:2018-11-22
通讯作者: 曹春雨 E-mail:2799087157@qq.com
基金资助:
抗酶抑制因子-1 介导肿瘤细胞发生免疫原性转化的实验研究;基于裸小鼠PDX模型的HDAC抑制剂抗三阴性乳腺癌研究

Advance of research study on histone deacetylase-targeted anti-triple negative breast cancer

Received:2017-06-22 Revised:2017-11-03 Online:2018-11-05 Published:2018-11-22
Contact: Chun-Yu CAO E-mail:2799087157@qq.com
Supported by:
Experimental study of AZIN-1 mediated tumor immunicity transformation;Anti-triple negative breast cancer study of HDAC inhibitors in PDX nude mice model

摘要/Abstract

摘要： 组蛋白去乙酰化酶异常高表达促进多种肿瘤的增殖、侵袭和转移，是新近鉴定的抗三阴性乳腺癌（TNBC）治疗靶点。近年来已研发多种组蛋白去乙酰化酶（HDAC）抑制剂广泛用于抗肿瘤基础研究与临床治疗。本文综述了HDAC家族蛋白参与TNBC发生的分子机制和HDAC抑制剂用于抗TNBC治疗的研究进展，讨论了目前HDAC抑制剂的局限性、未来研发方向和以HDAC为靶点的抗TNBC研究新策略。

关键词: 组蛋白去乙酰化酶, 三阴性乳腺癌, 组蛋白去乙酰化酶抑制剂

Abstract: Abnormal high expression of Histone deacetylase(HDAC) promotes malignant proliferation of many kinds of tumor and has been identified as a new target for anti-triple negative breast cancer (TNBC) therapy. In view of the important role of HDACs played in tumorigenesis, a variety of HDAC inhibitors have been developed and widely used in basic research and clinical treatment of cancer. This paper reviewed the latest research progress of HDAC promote TNBC generation and the development and application of HDAC inhibitor in anti-TNBC therapy.

Key words: histone deacetylase, triple negative breast cancer, histone deacetylase inhibitor

中图分类号:

王发玲谢珂王艳林曹春雨. 以HDAC为靶点的抗三阴性乳腺癌研究进展[J]. 基础医学与临床, 2018, 38(11): 1625-1629.

[1]	肖前仁黄路张中卒张战民陈少卿舒勇曹凯. RNA干扰组蛋白去乙酰化酶4抑制骨肉瘤细胞诱导凋亡[J]. 基础医学与临床, 2016, 36(12): 1693-1698.
[2]	王红晖;万玉民;李莹辉. Ⅱ类组蛋白去乙酰化酶与临床[J]. 基础医学与临床, 2011, 31(1): 101-103.